 |
인쇄하기
취소
|
AstraZeneca to face Crestor generic challenge
The Britain-based AstaZeneca is expected to face a generic challenge to its blockbuster cholesterol drug Crestor (rosuvastatin calcium) by 50 Korean companies.
These local companies are seeking approval to sell a copycat version of Crestor aiming to launch its version in December as its re-examination was expired on October 30.
The domestic market for cholesterol treatments, the biggest-s...
These local companies are seeking approval to sell a copycat version of Crestor aiming to launch its version in December as its re-examination was expired on October 30.
The domestic market for cholesterol treatments, the biggest-s...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.